Michel Bazinet

Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial

Michel Bazinet, Victor Pântea, Valentin Cebotarescu et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 249 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +11

Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy

Michel Bazinet, Victor Pântea, Gheorghe Plăcintă et al. · Gastroenterology · 2020 · 232 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Outcome of sextant biopsy according to gland volume

Pierre I. Karakiewicz, Michel Bazinet, Armen Aprikian et al. · Urology · 1997 · 209 citations

Medicine, Oncology, Pathology +6

Prospective evaluation of prostate-specificantigen density and systematic biopsies for early detection of prosttic carcinoma

Michel Bazinet, Alaa Meshref, Claude Trudel et al. · Urology · 1994 · 177 citations

Medicine, Oncology, Urology +17

Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection

Mamun Al‐Mahtab, Michel Bazinet, Andrew Vaillant · PLoS ONE · 2016 · 176 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15